Sarepta Therapeutics, Inc.
SRPTHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic. The company carries a $1.72B market cap, placing it firmly in the small-cap category. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Market Cap
$1.72B
Beta
0.26
P/E (TTM)
46.43
P/E (Fwd)
5.96
EPS (TTM)
$0.35
EPS (Fwd)
$2.73
ROE
4.9%
ROA
0.0%
Cash
$653.2M
Total Debt
$1.05B
Free CF
$204.8M
52W Change
-58.9%
Annual Financials
Cash vs Debt
On the balance sheet, SRPT has $653.2M in cash with $1.05B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $204.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 4.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $933.0M (2022) to $2.20B (2025), reflecting a 136% increase over the period.
The relatively low beta of 0.26 suggests SRPT is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sarepta Therapeutics, Inc. and its sector.